• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·300406.SZ
Share

Beijing Strong Biotechnologies,Inc. Stocks

CN¥ 11.5Last Updated 14.07.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 971.70M

CN¥ 11.5
Key Takeaways

Risk factor

Fair trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Decent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Beijing Strong Biotechnologies, Inc. operates as a supplier of in-vitro diagnostic (IVD) solutions, encompassing both products and associated services, for markets within the People's Republic of China and globally. The firm's comprehensive product line includes offerings for clinical biochemistry, such as diagnostic reagents and sophisticated automated analyzers. Additionally, it provides coagulation-related items, including necessary reagents and automated analysis instrumentation. Furthermore, its serology division delivers blood type testing cards and advanced automated systems for blood grouping. This enterprise was established in 2001 and has its corporate headquarters situated in Beijing, China.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.07.2026 16:40

The second-largest U.S. bank saw a sharp increase in profits thanks to market volatility

14.07.2026 16:04

"Records Across the Board": JPMorgan Reports a 41% Increase in Quarterly Profit

14.07.2026 15:48

Morning in New York: News Flow Will Drive Volatility

14.07.2026 14:41

Shares of a small-cap AI solutions developer soared amid a sector-wide slump. Why?

14.07.2026 13:30

Risks for a neobank: Can Revolut Reach a $200 Billion Valuation?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026